公开(公告)号：US20210198268A1

公开(公告)日：2021-07-01

申请号：US17202320

申请日：2021-03-15

申请人： Purdue Pharma L.P. ,  Purdue Pharmaceuticals L.P. ,  Rhodes Technologies

发明人： Robert CHAPMAN ,  Lonn S. RIDER ,  Qi HONG ,  Robert KUPPER ,  Donald J. KYLE

IPC分类号： C07D489/08 ,  A61K9/20 ,  A61K9/14 ,  A61K9/48 ,  A61K31/485 ,  C07D489/04 ,  C07D489/02

摘要： In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

公开(公告)号：US20220280527A1

公开(公告)日：2022-09-08

申请号：US17569002

申请日：2022-01-05

申请人： Purdue Pharma L.P.

发明人： Michele HUMMEL ,  Donald J. KYLE ,  Laykea TAFESSE ,  Garth WHITESIDE

IPC分类号： A61K31/5386 ,  A61K31/402 ,  A61K31/421 ,  A61K31/4439 ,  A61K31/5377 ,  A61K9/00 ,  A61K31/4164 ,  A61K31/44 ,  A61K31/485 ,  A61P25/02 ,  A61K31/4174 ,  A61K31/455

摘要： This application relates to using trace amine associated receptor 1 (TAARI) agonists and/or partial agonists for treating or preventing pain, especially neuropathic pain.

公开(公告)号：US20170319670A1

公开(公告)日：2017-11-09

申请号：US15412329

申请日：2017-01-23

申请人： Purdue Pharma L.P.

发明人： Donald J. KYLE ,  Daniel A. Soltis ,  Lynda G. Tussey

IPC分类号： A61K39/00 ,  C07K7/06 ,  C07K14/47 ,  G01N33/68 ,  G01N33/50 ,  C12N9/02 ,  C12N9/12

CPC分类号： A61K39/0005 ,  A61K39/00 ,  C07K7/06 ,  C07K14/4747 ,  C07K14/4748 ,  C12N9/0077 ,  C12N9/1241 ,  G01N33/505 ,  G01N33/6878 ,  G01N2333/70539 ,  G01N2500/04 ,  G01N2500/10

摘要： The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.

公开(公告)号：US20160022787A1

公开(公告)日：2016-01-28

申请号：US14820194

申请日：2015-08-06

申请人： Purdue Pharma L.P.

发明人： Donald J. KYLE ,  Daniel A. Soltis ,  Lynda G. Tussey

IPC分类号： A61K39/00

CPC分类号： A61K39/0005 ,  A61K39/00 ,  C07K7/06 ,  C07K14/4747 ,  C07K14/4748 ,  C12N9/0077 ,  C12N9/1241 ,  G01N33/505 ,  G01N33/6878 ,  G01N2333/70539 ,  G01N2500/04 ,  G01N2500/10

摘要： The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.

摘要翻译： 本发明通过提供作为MHC I类限制性抗原的肽衍生物来提供更有效的T细胞免疫应答发生器的合成。 本发明的肽衍生物是长度为8至11个氨基酸残基的母体肽制备或衍生的，其中肽衍生物含有非天然氨基酸代替天然存在的氨基酸残基 在母体肽中或位置6，位置7或C-末端具有更多的主要锚定位置。

公开(公告)号：US20240058333A1

公开(公告)日：2024-02-22

申请号：US18343182

申请日：2023-06-28

申请人： Purdue Pharma L.P.

发明人： Stephen C. HARRIS ,  Ram P. KAPIL ,  Donald J. KYLE ,  Garth WHITESIDE

IPC分类号： A61K31/498 ,  A61P25/20

CPC分类号： A61K31/498 ,  A61P25/20 ,  A61M21/00

摘要： The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of Formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.

公开(公告)号：US20190282836A1

公开(公告)日：2019-09-19

申请号：US16318686

申请日：2017-07-25

申请人： Purdue Pharma L.P.

发明人： Stephen C. HARRIS ,  Ram P. KAPIL ,  Donald J. KYLE ,  Garth WHITESIDE

IPC分类号： A61P25/20 ,  A61K31/498

摘要： The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.

公开(公告)号：US20140187571A1

公开(公告)日：2014-07-03

申请号：US14138380

申请日：2013-12-23

申请人： Purdue Pharma L.P.

发明人： Donald J. KYLE ,  Laykea Tafesse ,  Xiaoming Zhou

IPC分类号： C07D215/14

CPC分类号： C07D215/14 ,  C07D471/08

摘要： The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein Cy, R1a-R3a, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

摘要翻译： 本申请涉及式I-A化合物及其药学上可接受的盐和溶剂合物，其中Cy，R 1a -R 3a，R 4a和R 4b如本说明书所述定义。 本发明还涉及使用式I-A的化合物来治疗对一种或多种阿片样物质受体的调节或作为合成中间体的病症。 本发明的某些化合物特别适用于治疗疼痛。

公开(公告)号：US20230293516A1

公开(公告)日：2023-09-21

申请号：US18152399

申请日：2023-01-10

申请人： Purdue Pharma L.P.

发明人： Stephen C. HARRIS ,  Ram P. KAPIL ,  Donald J. KYLE ,  Garth WHITESIDE

IPC分类号： A61K31/498 ,  A61P25/20 ,  A61P25/32 ,  A61K9/00 ,  A61K31/138 ,  A61K31/145 ,  A61K31/16 ,  A61K31/197 ,  A61K31/485 ,  A61K31/554 ,  A61K31/7048

CPC分类号： A61K31/498 ,  A61P25/20 ,  A61P25/32 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/138 ,  A61K31/145 ,  A61K31/16 ,  A61K31/197 ,  A61K31/485 ,  A61K31/554 ,  A61K31/7048

摘要： The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.

公开(公告)号：US20210330994A1

公开(公告)日：2021-10-28

申请号：US17195434

申请日：2021-03-08

申请人： Purdue Pharma L.P.

发明人： Stephen C. HARRIS ,  Ram P. KAPIL ,  Donald J. KYLE ,  Garth WHITESIDE

IPC分类号： A61P25/20 ,  A61K31/498

摘要： The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.

公开(公告)号：US20200345726A1

公开(公告)日：2020-11-05

申请号：US16964174

申请日：2019-01-22

申请人： Purdue Pharma L.P.

发明人： Stephen C. HARRIS ,  Ram P. KAPIL ,  Donald J. KYLE ,  Garth WHITESIDE

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61K31/145 ,  A61K31/485 ,  A61K31/16 ,  A61K31/197 ,  A61K31/7048 ,  A61K31/138 ,  A61K31/554 ,  A61P25/32 ,  A61P25/20

摘要： The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.